BCL-2 inhibitor plus HyperCVAD for T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests adding a BCL-2 inhibitor drug to a standard chemotherapy regimen (HyperCVAD) for people newly diagnosed with T-cell lymphoblastic lymphoma. The goal is to see if the combination works better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 60 years old.
- Your overall health should be good enough for daily activities (ECOG score 0–2).
- Your heart, liver, kidneys, and lungs must be working well (checked by blood tests and scans).
- You cannot have active serious infections (like uncontrolled hepatitis, HIV, or tuberculosis).
- You should not have had treatment for this type of lymphoma before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs (thiotepa, cyclophosphamide, clarithromycin, and cytarabine) before a stem cell transplant. It is for people with certain types of blood cancer who have responded well to earlier treatment.
This trial tests a combination of three drugs (bendamustine, chidamide, and lenalidomide) for patients with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to see if this new combination can help when standard treatments have failed.
This trial tests a combination of medicines (Pola-R-CHP plus a new drug called Sonrotoclax) for newly diagnosed aggressive B-cell lymphoma, especially cases with high BCL-2 protein or double-hit features. The goal is to see if adding Sonrotoclax helps control the cancer better.
This trial tests if a new drug combination works better than the standard treatment for people with a specific, aggressive form of diffuse large B-cell lymphoma (DLBCL) that shows high levels of two proteins, MYC and BCL2. The study aims to improve outcomes by using genetic information to guide treatment choices.
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
This trial tests a two-step treatment for patients with an aggressive type of blood cancer (large B-cell lymphoma) that has come back or didn't respond well to standard therapy. You'll receive a stem cell transplant followed by CAR-T cells—specially engineered immune cells designed to fight cancer.
Hear when a new Lymphoblastic Lymphoma, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.